Drug news

FDA approves Healon EndoCoat OVD (Abbott Medical Optics) for use in Cataract extraction

Read time: 1 mins

Last updated:4th Jul 2012

Published:4th Jul 2012

Source: Pharmawand

The FDA has approved the use of Healon EndoCoat OVD, from Abbott Medical Optics, an ophthalmic viscosurgical device intended for use as a surgical aid in Cataract extraction and intraocular lens (IOL) implantation. This clear, viscous, protective gel formula is injected into a patient's eye to protect and coat the eye during surgery, reducing trauma to the inside layer of the cornea and other surrounding tissues. The surgical delivery system for Healon EndoCoat OVD is designed for increased patient safety and ease of handling for the physician, and has a smaller delivery device and improved ergonomics for a smooth and consistent delivery of the formula into the eye. Healon EndoCoat OVD is also available in Europe, Canada and New Zealand. The product will begin shipping immediately in the United States.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation for Tofidence (tocilizumab biosimilar)

Biogen Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Tofidence (tocilizumab), a biosimilar monoclonal antibody referencing Rocactemra

1 mins

Drug news

New data show Rinvoq (upadacitinib) demonstrated superiority versus Dupixent (dupilumab) across primary and all secondary endpoints in an open-label head-to-head atopic dermatitis study

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase IIIb/IV study that evaluated the efficacy and safety of upadacitinib (Rinvoq, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (Dupixent, per its labeled dose) in adults and adolescents (greater than 12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable

2 min

Drug news

FDA approves Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections

Utility Therapeutics received approval from the FDA for Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus

1 min

See all news